CSL Ltd
CSL Limited is an Australia-based biotechnology company.
The business
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news

Weekly wrap: Aussie shares sink 0.6% as US Bonds defy Bessent intervention
ASX slips 0.6% for the week as US yields rise despite Bessent's bid to push rates lower; property and tech slide, Zip plunges 15% amid inflation jitters.

Market wrap: ASX 200 moves above the 9000 point barrier on positive copper outlook
ASX 200 moves above 9,000 on copper outlook, with miners rallying as AI optimism lifts sentiment; inflation cools and rate hold bets intact.

Miners Rescue the War-Torn ASX Yet Again
Miners rescue ASX 200 as copper rally lifts Rio Tinto, BHP; Bravura soars on earnings; banks steady amid oil/war jitters.

ASX 200 climbs 1.37% to 8,844 as US payrolls miss; gold above 4,100
ASX 200 +1.37% to 8,844 as soft US payrolls lift Fed hold bets; gold rebounds above $4,100, capping choppy week ahead of FY26/FY27 open.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.